Reporting owner · CIK 0001965014

Shankar Gopi

SEC Form 4 history for the last 180 days across 1 company, 1 transaction and 1 filing.

CDOChief Development OfficerLarimar Therapeutics, Inc.
Open-market transaction mix100% buys1 buy · 0 sales

Period: Last 180 days

Trade dates in this period: Nov 11, 2026 – Nov 11, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$13.5k1 purchase
Selling$00 sales
Net value+$13.5kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Shankar Gopi transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
LRMRLarimar Therapeutics, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$13.5kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at Larimar Therapeutics, Inc. on Nov 11, 2026 valued at $13,549.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 202610$13,549$0+$13,549

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$13.5k
Median P/S size$13.5k
Direct1
Indirect0
Nov 11, 2026buy

Filing-only signals

Deterministic matches in this insider's history

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

1 observations · Nov 11, 2026 – Nov 11, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 11, 202681,443 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 11, 202681,443Nov 12, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Shankar Gopi Insider Activity FAQ

SEC Form 4 context

Who is Shankar Gopi?

Shankar Gopi is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001965014.

Which companies has Shankar Gopi reported transactions for?

Larimar Therapeutics, Inc.

When was Shankar Gopi's latest insider buy?

The insider reported a buy at Larimar Therapeutics, Inc. on Nov 11, 2026 valued at $13,549.

When was Shankar Gopi's latest insider sale?

No open-market insider sale is recorded in the last 180 days. Earlier filings are outside the visible history.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.